Posts by ericg
Top House leaders rule out Steward bailout
House Speaker Ron Mariano and Rep. Aaron Michlewitz sounded dubious as they discussed the bridge funding deal touted by a Steward executive to stave off hospital closures. Read More
Read MoreSynlogic cuts most workers after halting rare disease drug trial
The 10-year-old Cambridge biotech is saying good-bye to its chief executive and the vast majority of its staff after halting a Phase 3 trial that it said was unlikely to succeed. Read More
Read MoreThis Boston startup uses medical expertise to innovate the skin care industry
Founded by two MIT-educated women, Droplette is a skincare device and platform engineered to get products into the skin instead of just on top of it. Read More
Read MoreFive things: Boger’s back, wealthy college endowments and this is making your workers resentful
Good morning – you made it to Friday! Here are the five things you need to know: Josh Boger’s back, wealthy college endowments are growing, and this is making your workers resentful. Read More
Read MoreAn Asian food hub forms on a Brookline block, and more retail news
A group of new eateries will soon open on a block of Beacon Street in Brookline that’s becoming a hub for Asian food and drink. Here’s more on that and other area retail news. Read More
Read MoreMeet the real estate leader at Fallon Co. who isn’t named Fallon
It’s not for the faint of heart, taking on such a prominent role in a company named after the two other legs on that stool. Boston commercial real estate is in many ways a small world, with well-established local families playing a big role. Read More
Read MoreCommentary: The small-molecule ‘penalty’ is a threat to Mass. biotech sector
The Inflation Reduction Act inadvertently introduced a change in drug-development incentives that could result in distorted decisions about which treatments get developed. Read More
Read MoreFoghorn gets $300M plus investment from Lilly under cancer drug partnership
Foghorn Therapeutics saw its stock price soar on Thursday following the news that its collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, was bearing fruit. Read More
Read MoreFoghorn’s shares rise after Lilly chooses cancer drug for development
Foghorn Therapeutics saw its stock price soar on Thursday following the news that its collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, was bearing fruit. Read More
Read MoreIRS seeks information from small businesses that received ERC — and offers a way out
The new batch of letters shows how the agency is working every angle to combat fraud in the lucrative tax-credit program. Read More
Read More